A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

A Randomized, Double-blind, Non-inferiority, Multi-center, Phase 4 Trial to Evaluate the Blood Pressure Lowering Effect of a Candesartan/Hydrochlorothiazide(Candemore Plus® Tab) Versus Candesartan/Amlodipine(Cantabell® Tab) in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04521023

Enrollment

132

Registered

2020-08-20

Start date

2017-09-20

Completion date

2020-06-03

Last updated

2020-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Phase 4 clinical trial to Evaluate the blood pressure lowering effect of a Candesartan/Hydrochlorothiazide(Candemore Plus Tab) versus Candesartan/Amlodipine(Cantabell Tab) in Hypertensive Patients

Interventions

DRUGCantabell Tab

Patients assigned to experimental group are treated with Cantabell Tab

DRUGCandemore Plus Tab

Patients assigned to experimental group are treated with Candemore Plus Tab

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* over 19 years old * Agreement with written informed consent * Hypertensive Patients

Exclusion criteria

* Patients with secondary hypertension * Participated in other trial within 30 days * In investigator's judgement

Design outcomes

Primary

Measure	Time frame	Description
cSBP(central Systolic Blood Pressure)	change after 8 weeks compared to baseline	Average cSBP change after 8 weeks compared to baseline

Secondary

Measure	Time frame	Description
cDBP(central Diastolic Blood Pressure)	change after 8 weeks compared to baseline	Average cDBP change after 8 weeks compared to baseline
sitSBP(sitting Systolic Blood Pressure)	change after 8 weeks compared to baseline	Average sitSBP change after 8 weeks compared to baseline
sitDBP(sitting Diastolic Blood Pressure)	change after 8 weeks compared to baseline	Average sitDBP change after 8 weeks compared to baseline

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026